GO
Loading...

CVS Health Corp

More

  • Feb 18- Samsung Electronics Co Ltd has bought U.S. mobile wallet startup LoopPay, signalling its intention to launch a smartphone payments service to compete with a recent offering from rival Apple Inc.. Apple, Google, and eBay Inc's PayPal have all launched services to allow users to pay in stores via smartphones. He would not be drawn on speculation the company...

  • Feb 17- CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place." CVS' call for cost controls follows sharp criticism from insurers, other payers and...

  • Feb 17- CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year. The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000- $12,000 per year, CVS said.

  • Cigarettes & health do not mix: CVS CEO   Friday, 13 Feb 2015 | 8:48 AM ET
    Cigarettes & health do not mix: CVS CEO

    David Dorman, CVS Health non-executive chairman, discusses the upside of CVS's healthy sales record and the outlook on health care costs.

  • Feb 11- Drugstore operator Rite Aid Corp agreed to buy pharmacy benefit manager EnvisionRx for about $2 billion, looking to cut drug procurement costs as reimbursement rates fall. Rite Aid's deal comes nearly a decade after larger rival CVS Health Corp bought Caremark Rx for $21 billion, the only other example of a drug chain buying a benefits manager.

  • Feb 11- Drugstore operator Rite Aid Corp said it would buy pharmacy benefit manager EnvisionRx for about $2 billion, entering the business of administering health plan benefits. The deal will help Rite Aid compete better with CVS Health Corp, which bought Caremark Rx for $21 billion in 2006.. The acquisition of EnvisionRx will also give Rite Aid access to more...

  • Don't miss these rewards programs   Tuesday, 10 Feb 2015 | 3:15 PM ET
    Don't miss these rewards programs

    Billions of consumers belong to rewards programs. These are the most worthwhile.

  • Greeks soften tone as Germans stand firm Tuesday, 10 Feb 2015 | 11:37 AM ET
    Pharmacist George Bacacos, right, behind the counter at his drugstore.

    Recommendations from the OECD may form the basis of a deal sought by Greece with euro zone finance ministers.

  • Wyndham CEO: Strong dollar, minimal impact   Tuesday, 10 Feb 2015 | 10:30 AM ET
    Wyndham CEO: Strong dollar, minimal impact

    Discussing Q4 earnings, Stephen Holmes, Wyndham Worldwide CEO, says the company is not terribly impacted by a strong dollar.

  • Analyst: CVS's elimination of tobacco offered 'wide-spread benefit'

    Meredith Adler, food and drug analyst at Barclays Capital, discusses the significance of CVS's beat on the top line. Adler still likes the stock.

  • Feb 10- CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales. CVS became the first national drugstore chain in the United States to take cigarettes off its shelves from Oct. 1. CVS Health has focused on developing its specialty pharmacy business, which sells drugs...

  • Feb 10- CVS Health Corp, the No. 2 U.S. drugstore operator, reported a better-than-expected quarterly net revenue, helped by a jump in pharmacy same-store sales and strength in its specialty pharmacy business. CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid...

  • Early movers: KO, CVS, HOT, HD, GPS & more Tuesday, 10 Feb 2015 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange, Feb. 9, 2015.

    Some of the names on the move ahead of the open.

  • Will early data back up the blowout jobs report? Tuesday, 10 Feb 2015 | 6:41 AM ET
    A now-hiring sign is shown in the window of a Panera Bread store in Santa Monica, Calif.

    Investors are looking at further confirmation of an improving U.S. job market with two data points that come out on Tuesday.

  • Here's how a janitor amassed an $8M fortune Monday, 9 Feb 2015 | 6:44 PM ET
    In this December 2011 photo, Connie Howe pours coffee for Ronald Read, left, and Dave Smith during the Charlie Slate Memorial Christmas breakfast at the American Legion in Brattleboro, Vt.

    A Vermont gas station attendant and janitor, invested in recognizable names when he amassed an $8 million fortune, his attorney said.

  • Cramer game plan: Next week's hot stocks to watch Friday, 6 Feb 2015 | 6:09 PM ET
    Game plan strategy

    Jim Cramer sees that the market is in a sweet spot for earnings. With a new landscape, he's betting that these are the hot stocks to watch.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Doctors' group joins fight against high drug prices Tuesday, 3 Feb 2015 | 3:34 PM ET
    An undated handout photo provided by Gilead Sciences shows the hepatitis-C medication Sovaldi.

    A leading group of physicians is warning that high prices of specialty drugs is creating barriers to care for patients.

  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.